Therapeutic Asset Ratings

461 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
DEXAMETHASONE BCMA	Pfizer	P2	B (57)
DEXAMETHASONE BCMA-CD3 Bispecific	Pfizer	P2	B (57)
DEXAMETHASONE Bispecific	Pfizer	P2	B (57)
DEXAMETHASONE Bispecific Antibody	Pfizer	P2	B (57)
Elranatamab BCMA	Pfizer	P2	B (57)
Elranatamab BCMA-CD3 Bispecific	Pfizer	P2	B (57)
Elranatamab Bispecific	Pfizer	P2	B (57)
Elranatamab Bispecific Antibody	Pfizer	P2	B (57)
Fludarabine Lung Neoplasm	Pfizer	P2	B (57)
FULVESTRANT Triple-Negative Breast Carcinoma	Pfizer	P2	B (57)
Letrozole Lung Adenocarcinoma	Pfizer	P2	B (57)
met097 Diabetes Mellitus	Pfizer	P2	B (57)
met097 Type 2 Diabetes Mellitus	Pfizer	P2	B (57)
Mezigdomide BCMA	Pfizer	P2	B (57)
Mezigdomide BCMA-CD3 Bispecific	Pfizer	P2	B (57)
Mezigdomide Bispecific	Pfizer	P2	B (57)
Mezigdomide Bispecific Antibody	Pfizer	P2	B (57)
Palbociclib Rhabdomyosarcoma	Pfizer	P2	B (57)
Palbociclib Medulloblastoma	Pfizer	P2	B (57)
Palbociclib Neuroblastoma	Pfizer	P2	B (57)
Palbociclib Rhabdoid Tumor	Pfizer	P2	B (57)
Palbociclib Refractory Rhabdomyosarcoma	Pfizer	P2	B (57)
met233 Obesity Disorder	Pfizer	P1/2	B (57)
Cytosin-Arabinosid Lung Cancer	Pfizer	P3	B (56)
Daunorubicin Lung Cancer	Pfizer	P3	B (56)

Showing 126 to 150 of 461 assets